Does Amerigroup Cover Forteo?

How Amerigroup Classifies Forteo on Its Formulary

Amerigroup places Forteo on the specialty tier of most formularies, which means higher cost-sharing and mandatory dispensing through a designated specialty pharmacy. Because Amerigroup operates as a Medicaid managed care organization in more than 20 states and also offers Medicare Advantage and ACA marketplace plans, formulary placement can shift depending on the specific product line and state contract.

On Medicaid managed care plans, state Medicaid agencies set the preferred drug list (PDL), and Amerigroup must cover at least one parathyroid hormone analog when medically necessary 1. In practice, teriparatide appears on most state PDLs as a non-preferred specialty agent, meaning coverage is available but subject to clinical criteria. Medicare Advantage formularies follow CMS Part D guidelines that classify teriparatide under Tier 5 (specialty), with typical coinsurance of 25% to 33% after the deductible 2. ACA marketplace plans offered by Amerigroup in states like Texas, Georgia, and Tennessee generally mirror this specialty-tier placement.

The key takeaway: Forteo is coverable, not automatically covered. The distinction matters. Your prescriber will need to file paperwork proving you meet specific clinical thresholds before Amerigroup authorizes payment.

Prior Authorization Requirements for Forteo

Every Amerigroup plan line requires prior authorization (PA) for Forteo. The PA criteria follow a predictable pattern across states, though exact documentation requirements vary.

Standard criteria include a confirmed diagnosis of osteoporosis with a DXA T-score of -2.5 or below at the lumbar spine, femoral neck, or total hip 3. Amerigroup also accepts a history of fragility fracture (vertebral or hip) as qualifying evidence, even without a T-score meeting the -2.5 threshold. The American Association of Clinical Endocrinologists (AACE) 2020 guidelines recommend anabolic therapy as first-line for patients at "very high" fracture risk, defined as a recent fracture within 12 months, T-score below -3.0, or a FRAX 10-year major osteoporotic fracture probability exceeding 30% 4.

Amerigroup typically requires documentation of the following before approving Forteo:

• Diagnosis of osteoporosis confirmed by DXA scan or fragility fracture history
• Trial and failure, intolerance, or contraindication to at least one oral bisphosphonate (alendronate 70 mg weekly or risedronate 35 mg weekly, taken for a minimum of 12 months)
• Prescriber must be or consult with an endocrinologist, rheumatologist, or orthopedic specialist
• Patient has no history of Paget disease, unexplained alkaline phosphatase elevation, prior radiation therapy to the skeleton, or open epiphyses
• Lifetime use limited to 24 months total

PA approvals are generally granted for 6 to 12 months at a time. Reauthorization requires updated clinical notes showing treatment response, typically a repeat DXA or documented absence of new fractures.

Step Therapy: Which Drugs Must You Try First?

Amerigroup enforces step therapy for Forteo on all plan types. This is not optional.

The rationale is cost-driven but also evidence-based. Oral bisphosphonates remain the most studied class for fracture reduction in osteoporosis, with alendronate reducing hip fracture risk by 51% in the Fracture Intervention Trial (FIT; N=2,027) 5. Amerigroup requires at least one adequate trial, defined as 12 or more months of consistent use at therapeutic dose with either continued bone loss on repeat DXA, new fracture, or documented adverse effects such as esophagitis or osteonecrosis of the jaw.

In some states, Amerigroup's step therapy protocol also requires a trial of IV zoledronic acid (Reclast) before approving Forteo. Zoledronic acid 5 mg IV once yearly reduced vertebral fracture risk by 70% and hip fracture risk by 41% in the HORIZON Key Fracture Trial (N=7,765) 6. If you cannot tolerate IV bisphosphonates due to renal impairment (eGFR <35 mL/min) or documented infusion reactions, this step can be bypassed with supporting documentation.

Contraindications that bypass step therapy entirely include:

• Esophageal disorders (achalasia, stricture, Barrett esophagus) that preclude oral bisphosphonate use
• Chronic kidney disease stage 4 or 5 (eGFR <30 mL/min), which contraindicates both oral and IV bisphosphonates
• Glucocorticoid-induced osteoporosis where the ACR 2022 guidelines recommend anabolic agents as initial therapy for patients on prednisone 7.5 mg/day or higher for 3 or more months 7

Your physician should document these contraindications in the PA submission letter with supporting lab values, imaging, and procedural notes.

What Will Forteo Cost You Through Amerigroup?

Out-of-pocket cost depends entirely on your plan type. The spread is wide.

Medicaid managed care members in most states pay $0 to $3 per prescription for specialty medications. Federal Medicaid rules cap cost-sharing, so even a Tier 5 drug like Forteo carries minimal copays for Medicaid enrollees 8. This makes Amerigroup Medicaid plans the most affordable pathway to Forteo access.

Medicare Advantage members face the standard Part D benefit structure. After meeting the annual deductible (typically $545 in 2025), specialty-tier coinsurance runs 25% to 33%. Given Forteo's average wholesale price near $4,100 per 28-day pen, that translates to roughly $1,025 to $1,353 per month before catastrophic coverage kicks in. Once total out-of-pocket spending hits $8,000 (the 2025 Medicare out-of-pocket cap under the Inflation Reduction Act), monthly costs drop to $0 for the remainder of the calendar year 9.

ACA marketplace plans through Amerigroup vary by metal tier. Silver and Gold plans with integrated pharmacy benefits typically apply 20% to 40% coinsurance for specialty drugs. Manufacturer copay assistance from Eli Lilly (the Forteo Savings Card) can reduce costs by up to $600 per month for commercially insured patients, though this assistance does not apply to government-funded plans like Medicaid or Medicare.

How to File a Forteo Prior Authorization With Amerigroup

The PA process is administrative but manageable when your prescriber submits complete documentation on the first attempt. Incomplete submissions are the primary reason for initial denials.

Your prescriber or their staff should call Amerigroup's pharmacy prior authorization line or submit electronically through CoverMyMeds. The submission needs to include the following:

• Current DXA scan results with T-scores at all measured sites
• Documentation of prior bisphosphonate therapy, including drug name, dose, duration, and reason for discontinuation
• Fracture history with imaging reports if applicable
• Relevant lab work (calcium, vitamin D, PTH, alkaline phosphatase, renal function)
• A letter of medical necessity from the treating specialist

Turnaround time for standard PA requests is 72 hours for non-urgent cases and 24 hours for expedited (urgent) requests. The Endocrine Society's 2020 clinical practice guideline states that teriparatide is "recommended for patients with osteoporosis at high risk for fracture, including those with severe or multiple vertebral fractures" 10. Citing this guideline language directly in the letter of medical necessity strengthens the submission.

If the initial PA is denied, your provider can request a peer-to-peer review with an Amerigroup medical director within 5 business days. This call often resolves denials that stem from missing documentation rather than true clinical ineligibility.

What to Do If Amerigroup Denies Coverage

Denials happen. They are not final.

The first step after a denial is reading the denial letter carefully. Amerigroup must specify the clinical reason for the denial, whether it is incomplete step therapy, insufficient documentation, or a determination that the drug is not medically necessary for your situation. Each reason demands a different response.

For step therapy denials, the fix is usually submitting records proving prior bisphosphonate use. If your previous provider prescribed alendronate and you switched insurance, pharmacy claims data from the prior plan may need to be obtained. Your current pharmacist can run a medication history through SureScripts to document dispensing records.

For medical necessity denials, a formal appeal through Amerigroup's internal grievance process is the next step. You have 60 days from the denial notice to file. Include updated clinical notes, any new imaging, and a detailed letter from your physician explaining why Forteo is the appropriate therapy. The AACE guideline's classification of "very high fracture risk" as warranting anabolic therapy provides strong supporting language 4.

If the internal appeal fails, every state offers an external review process through an independent review organization (IRO). The IRO's decision is binding on Amerigroup. According to CMS data, external appeals for specialty drug denials are overturned in approximately 40% to 60% of cases when supported by guideline-concordant documentation 11.

Covered Alternatives to Forteo on Amerigroup Plans

If Forteo is denied or cost-prohibitive, several alternatives may be available on your Amerigroup formulary at lower cost-sharing tiers.

Teriparatide biosimilar (generic teriparatide). The FDA approved generic teriparatide in 2023, and several manufacturers now offer it at roughly 30% to 50% lower cost than branded Forteo. Amerigroup may prefer the generic version and auto-substitute at the pharmacy level. Clinical equivalence was established through bioequivalence studies required by the FDA's abbreviated pathway 2.

Abaloparatide (Tymlos). This PTHrP analog received FDA approval in 2017 and reduced new vertebral fractures by 86% versus placebo in the ACTIVE trial (N=2,463) 12. Some Amerigroup formularies list Tymlos as an alternative to Forteo, though it is also classified as specialty tier with PA requirements.

Romosozumab (Evenity). A sclerostin inhibitor approved in 2019, romosozumab reduced vertebral fracture risk by 73% versus alendronate in the ARCH trial (N=4,093) at 12 months 13. Amerigroup covers Evenity on some plans but applies similar or stricter PA criteria. Cardiovascular risk screening is required because of the FDA boxed warning regarding potential MI and stroke risk.

Denosumab (Prolia). An anti-RANK ligand antibody administered as a subcutaneous injection every 6 months. The FREEDOM trial (N=7,868) demonstrated a 68% reduction in vertebral fractures over 3 years 14. Denosumab is antiresorptive rather than anabolic, so it works through a different mechanism than Forteo. Amerigroup frequently places Prolia on a lower specialty tier than Forteo, making it more accessible as a first-line injectable option.

Oral bisphosphonates (alendronate, risedronate, ibandronate). These remain Tier 1 or Tier 2 on all Amerigroup plans with copays typically under $10. Generic alendronate 70 mg weekly costs approximately $4 to $12 per month at retail. While they are antiresorptive agents rather than bone-building drugs, they remain the most commonly prescribed osteoporosis medications in the United States, with over 30 million prescriptions dispensed annually 15.

Specialty Pharmacy and Delivery Logistics

Amerigroup requires Forteo to be dispensed through a contracted specialty pharmacy. You cannot fill this prescription at a standard retail pharmacy.

Common specialty pharmacy partners for Amerigroup include Accredo (an Express Scripts subsidiary), CVS Specialty, and in some states, local specialty pharmacy networks. The specialty pharmacy coordinates delivery directly to your home, typically via cold-chain shipping since teriparatide requires refrigeration at 2°C to 8°C.

Before your first shipment, the specialty pharmacy will conduct an intake call to review injection technique, storage requirements, and potential side effects. Forteo is self-administered as a daily subcutaneous injection in the thigh or abdomen using a prefilled pen device. Each pen contains a 28-day supply. Common injection-site reactions include redness, swelling, and mild pain, reported in approximately 10% of patients in clinical trials 1.

Refills are coordinated by the specialty pharmacy on a recurring schedule. Expect a call or text 5 to 7 days before your next shipment is due. If you travel, request an early fill through Amerigroup's specialty pharmacy team at least 2 weeks in advance, and arrange for a portable cooler to maintain proper storage temperature during transit.

Duration Limits and Transition Planning

The FDA limits teriparatide use to a maximum of 24 months over a patient's lifetime. Amerigroup enforces this limit through PA duration controls.

This cap exists because of preclinical findings in Fischer 344 rats, where lifelong high-dose teriparatide exposure was associated with osteosarcoma. No causal link has been established in humans. A post-marketing surveillance study of over 600,000 teriparatide-treated patients found no statistically significant increase in osteosarcoma incidence 16.

After completing a Forteo course, transitioning to an antiresorptive agent is standard practice. Bone mineral density gains from teriparatide are rapidly lost if no follow-on therapy is prescribed. The DATA-Switch trial demonstrated that women who received 2 years of teriparatide followed by 2 years of denosumab achieved the greatest cumulative BMD gains at both the spine (+18.3%) and hip (+6.6%) 17. Amerigroup covers denosumab and oral bisphosphonates as follow-on therapy, and your prescriber should submit a new PA for the transition medication approximately 4 to 6 weeks before your final Forteo pen runs out.

Repeat DXA scanning is recommended 1 to 2 years after completing teriparatide, per the International Society for Clinical Densitometry (ISCD) guidelines, to assess treatment response and guide ongoing therapy decisions 3.